Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 136.22

-0.8%

Jan 23 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1229)	6/22/2004 2:00:07 PM
From: Icebrg	Read Replies (1) of 1834

Neurocrine Biosciences "outperform" Monday, June 21, 2004 1:02:16 PM ET Piper Jaffray NEW YORK, June 21 (New Ratings) - Analyst Thomas Wei of Piper Jaffray maintains his "outperform" rating on Neurocrine Biosciences (NBIX.NAS). In a research note published this morning, the analyst mentions that the company's share price has declined recently over investor concerns regarding a delay in the filing of the Indiplon-MR drug. However, the analyst expresses his optimism regarding the company's ability to file for the FDA approval of Indiplon-MR on schedule. According to Piper Jaffray, Neurocrine Biosciences and its partner, Pfizer, are on track to launch Indiplon-MR in the US during 2H05.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next